Tracking glucose tolerance in patients with type 2 diabetes using technology
A Participatory Approach to Support Glucose Tolerance Tracking in Real-Life of Patients With Type 2 Diabetes
This study is testing if using continuous glucose monitors and health tracking devices can help people with type 2 diabetes who aren't on insulin make better lifestyle choices to manage their blood sugar levels.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 20 (estimated) |
| Ages | 40 Years to 70 Years |
| Sex | All |
| Sponsor | University of Pavia Academic / other |
| Locations | 1 site (Pavia, Pavia) |
| Trial ID | NCT06864546 on ClinicalTrials.gov |
What this trial studies
This study aims to enhance the management of type 2 diabetes through a participatory e-health approach that utilizes continuous glucose monitors (CGM) and other health tracking devices. By collecting real-time health data from patients, the study will develop an easy-to-use tool for tracking metabolic status and analyze the relationship between lifestyle changes and glucose levels. The focus is on sedentary individuals with type 2 diabetes who are not on insulin treatment, promoting lifestyle interventions to improve their health outcomes.
Who should consider this trial
Good fit: Ideal candidates for this study are sedentary individuals aged 40 to 70 with non-insulin treated type 2 diabetes.
Not a fit: Patients who have been diagnosed with diabetes for less than three years or those with significant heart disease may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could empower patients to better manage their diabetes and potentially reverse their condition through lifestyle changes.
How similar studies have performed: While many studies have shown success with CGM devices in type 1 diabetes and advanced type 2 diabetes, this approach in non-insulin treated type 2 diabetes is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Non-insulin treated T2D diagnosis (not treated at all or only with metformin); * Physically inactive (less than 150 minutes/week of moderate physical activity); * Age between 40 and 70; * HbA1c below 8.5%. Exclusion Criteria: * Diabetes diagnosis less than 3 years before the study initiation; * Pregnancy; * Symptomatic heart disease, e.g. history of myocardial infarction, coronary bypass, stenting procedure, angina, or any ischemic cerebrovascular event; * Use of a medication that significantly impacts glucose metabolism (oral steroids); * Use of a medication that significantly lowers heart rate (beta blockers, reserpine, guanethidine, methyldopa, clonidine, cimetidine, digitalis, calcium channel blockers, amiodarone, antiarrhythmic drugs, or lithium); * Atrial fibrillation; * Use of an electronic pacemaker.
Where this trial is running
Pavia, Pavia
- Istituti Clinici Scientifici Maugeri di Pavia — Pavia, Pavia, Italy (Recruiting)
Study contacts
- Study coordinator: Enea Parimbelli
- Email: enea.parimbelli@unipv.it
- Phone: +39 0382 9895981
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.